Sumitomo Dainippon Pharma Co Ltd (4506.D)
22 Sep 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|59||2017||Senior Managing Executive Officer, Representative Director|
|60||2016||Managing Executive Officer, Chief Director of Sales, Director|
|2017||Managing Executive Officer, Chief Director of Production|
|2017||Managing Executive Officer|
|2017||Managing Executive Officer, Chairman & Chief Executive Officer of Subsidiary|
- BRIEF-Sumitomo Dainippon Pharma U.S.-based unit enters agreement to divest asthma and allergy products to Covis pharma
- BRIEF- Sumitomo Dainippon Pharma unit Sunovion announces FDA acceptance for review of new drug application resubmission for SUN-101
- BRIEF- Sumitomo Chemical unit Sumitomo Dainippon Pharma announces unblinding of phase 3 study of Napabucasin
- BRIEF- Sumitomo Dainippon Pharma announces application of International Financial Reporting Standards
- BRIEF-Sumitomo Dainippon Pharma unit receives Complete Response Letter from FDA for SUN-101/eFlow® New Drug Application for chronic obstructive pulmonary disease